These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26927951)

  • 1. Antipsychotic Management of Schizoaffective Disorder: A Review.
    Lindenmayer JP; Kaur A
    Drugs; 2016 Apr; 76(5):589-604. PubMed ID: 26927951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder.
    Chue P; Chue J
    Ther Clin Risk Manag; 2016; 12():109-16. PubMed ID: 26869795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
    Glick ID; Correll CU; Altamura AC; Marder SR; Csernansky JG; Weiden PJ; Leucht S; Davis JM
    J Clin Psychiatry; 2011 Dec; 72(12):1616-27. PubMed ID: 22244023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
    J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizoaffective disorder: A review.
    Miller JN; Black DW
    Ann Clin Psychiatry; 2019 Feb; 31(1):47-53. PubMed ID: 30699217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of schizoaffective disorder and schizophrenia with mood symptoms.
    Levinson DF; Umapathy C; Musthaq M
    Am J Psychiatry; 1999 Aug; 156(8):1138-48. PubMed ID: 10450252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What we know and what we don't know about the treatment of schizoaffective disorder.
    Murru A; Pacchiarotti I; Nivoli AM; Grande I; Colom F; Vieta E
    Eur Neuropsychopharmacol; 2011 Sep; 21(9):680-90. PubMed ID: 21565468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
    Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
    J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence.
    Greenberg WM; Citrome L
    Neurol Ther; 2015 Dec; 4(2):81-91. PubMed ID: 26662360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
    Williams W; McKinney C; Martinez L; Benson C
    J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatments for late-life bipolar disorder.
    Aziz R; Lorberg B; Tampi RR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):347-64. PubMed ID: 17296540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.